Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Windlas Biotech's share price for the quarter that ended in Mar. 2026 was ₹736.75. Windlas Biotech's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 21 Mil. Therefore, Windlas Biotech's market cap for the quarter that ended in Mar. 2026 was ₹15,550 Mil.
Windlas Biotech's quarterly market cap
declined
from Sep. 2025 (₹19,093 Mil) to Dec. 2025 (₹16,757 Mil) and
declined
from Dec. 2025 (₹16,757 Mil) to Mar. 2026 (₹15,550 Mil).
Windlas Biotech's annual market cap
increased
from Mar. 2024 (₹10,614 Mil) to Mar. 2025 (₹21,808 Mil) but then
declined
from Mar. 2025 (₹21,808 Mil) to Mar. 2026 (₹15,550 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Windlas Biotech's Enterprise Value for Today is ₹15,308 Mil.
Windlas Biotech (NSE:WINDLAS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Windlas Biotech Market Cap Related Terms
Windlas Biotech Market Cap Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Windlas Biotech's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windlas Biotech (NSE:WINDLAS) has a Market Cap of ₹17,753 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Windlas Biotech and its competitors. According to the industry distribution chart, Windlas Biotech ranks #531 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 52.1%.
Is Windlas Biotech's Market Cap too high?
Windlas Biotech's current Market Cap is ₹17,753 Mil. Based on the distribution chart, Windlas Biotech ranks #531 out of 1020 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #531 out of 1020 companies for Market Cap. This places Windlas Biotech in the lower half of its industry. The industry median Market Cap is 204.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 204.29, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median Market Cap is 204.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current Market Cap is ₹17,753 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.98, compared to a current price of ₹859.00 — trading 8.3% below its estimated fair value. The current Market Cap is ₹17,753 Mil. Windlas Biotech's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Market Cap is ₹17,753 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹859.00 is trading 8.3% below its estimated GF Value™ of ₹936.98.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
Market Cap: ₹17,753 Mil
GF Value™: ₹936.98 vs. price of ₹859.00 (8.3% below fair value)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
86GF Score
Get the complete analysis for NSE:WINDLAS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
